West Pharmaceutical Services, Inc. WST NYSE

West Pharmaceutical Services, Inc. (WST) has shown moderate revenue growth over the past 3 years, expanding from $2.9B to $3.1B (average +2.2%/yr). Net income reached $494M, reflecting earnings decline at -5.2%/yr on average. The net profit margin is 16.1%, which is high. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 35.9% (moderate), with a -3.5pp trend over the period. With a $19B market cap and MOAT composite score of 57/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (30/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 41-year history, the company was profitable in 39 of 41 years — an excellent long-term track record
• INCOME (70/100, Pass) — proves strong profitability and pricing power
• MOAT (57/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 66/100 with 4/7 criteria passed.